Difference between revisions of "PMID:8524852"
(Table edited by Wameza via TableEdit) |
(Table edited by Wameza via TableEdit) |
||
Line 74: | Line 74: | ||
| | | | ||
As a result of the ''gyrA<sup>r</sup>'' mutation caused the accumulation of catenane due to the preferential inhibition of topo IV. See Figure 1B. | As a result of the ''gyrA<sup>r</sup>'' mutation caused the accumulation of catenane due to the preferential inhibition of topo IV. See Figure 1B. | ||
+ | | | ||
+ | |||
+ | |- | ||
+ | | | ||
+ | a mutation or genetic difference within a strain | ||
+ | | | ||
+ | *Taxon: Escherichia coli | ||
+ | *Strain: K-12 | ||
+ | *Substrain: 205096 | ||
+ | *NCBI Taxon ID: [http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&id=83333&lvl=3&lin=f&keep=1&srchmode=1&unlock 83333] | ||
+ | | | ||
+ | *Genotype of Reference Strain: ''gyrA<sup>+</sup>'' | ||
+ | *Genotype of Experimental Strain : ''gyrA<sup>R</sup>; S83L | ||
+ | | | ||
+ | *Reference Condition: | ||
+ | | | ||
+ | |||
+ | | | ||
+ | |||
+ | | | ||
+ | |||
+ | | | ||
+ | |||
+ | | | ||
+ | The mutation the ''gyrA<sup>r</sup>'' caused increased resistance to various quinolones. | ||
| | | | ||
Revision as of 12:20, 18 March 2013
Citation |
Khodursky, AB, Zechiedrich, EL and Cozzarelli, NR (1995) Topoisomerase IV is a target of quinolones in Escherichia coli. Proc. Natl. Acad. Sci. U.S.A. 92:11801-5 |
---|---|
Abstract |
We have demonstrated that, in Escherichia coli, quinolone antimicrobial agents target topoisomerase IV (topo IV). The inhibition of topo IV becomes apparent only when gyrase is mutated to quinolone resistance. In such mutants, these antibiotics caused accumulation of replication catenanes, which is diagnostic of a loss of topo IV activity. Mutant forms of topo IV provided an additional 10-fold resistance to quinolones and prevented drug-induced catenane accumulation. Drug inhibition of topo IV differs from that of gyrase. (i) Wild-type topo IV is not dominant over the resistant allele. (ii) Inhibition of topo IV leads to only a slow stop in replication. (iii) Inhibition of topo IV is primarily bacteriostatic. These differences may result from topo IV acting behind the replication fork, allowing for repair of drug-induced lesions. We suggest that this and a slightly higher intrinsic resistance of topo IV make it secondary to gyrase as a quinolone target. Our results imply that the quinolone binding pockets of gyrase and topo IV are similar and that substantial levels of drug resistance require mutations in both enzymes. |
Links | |
Keywords |
Anti-Bacterial Agents/pharmacology; Ciprofloxacin; DNA Gyrase; DNA Replication/drug effects; DNA Topoisomerase IV; DNA Topoisomerases, Type II/drug effects; DNA Topoisomerases, Type II/genetics; DNA, Bacterial/metabolism; Dose-Response Relationship, Drug; Drug Resistance, Microbial; Escherichia coli/drug effects; Escherichia coli/enzymology; Mutation; Norfloxacin/pharmacology; Nucleic Acid Conformation; Quinolones/pharmacology |
edit table |
Main Points of the Paper
Please summarize the main points of the paper.
Materials and Methods Used
Please list the materials and methods used in this paper (strains, plasmids, antibodies, etc).
Phenotype Annotations
See Help:AnnotationTable for details on how to edit this table.
<protect>
Phenotype of | Taxon Information | Genotype Information (if known) | Condition Information | OMP ID | OMP Term Name | ECO ID | ECO Term Name | Notes | Status |
---|---|---|---|---|---|---|---|---|---|
a mutation or genetic difference within a strain |
|
|
|
As a result of the gyrAr mutation caused the accumulation of catenane due to the preferential inhibition of topo IV. See Figure 1B. |
|||||
a mutation or genetic difference within a strain |
|
|
|
The mutation the gyrAr caused increased resistance to various quinolones. |
| ||||
edit table |
</protect>
Notes
- It was found that the tested drugs (nalidixic acid, ciprofloxacin, norfloxacin & various 2-pyridones) were 2 fold less effective on topo IV than on the gyrase despite their various Ki values. This indicates that the drugs were inhibitors of topo IV in vitro but none inhibited it preferentially.
References
See Help:References for how to manage references in omp dev.